Results 21 to 30 of about 1,442,988 (353)
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
Cancers, 2023 Simple Summary Multiple myeloma, a cancer of the bone marrow, is the commonest cancer of adults in the Western World. Therapies have advanced dramatically in recent years, equating to improved survival and quality of life for patients, but those with ...
D. Swan, P. Murphy, S. Glavey, J. Quinn
semanticscholar +1 more source
Bispecific antibodies and their applications [PDF]
Journal of Hematology & Oncology, 2015 Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Mingju Hao +3 more
openaire +3 more sources
Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities.
Blood, 2022 Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last two decades following the introduction of highly active immunotherapies, such as rituximab.
L. Falchi, S. Vardhana, G. Salles
semanticscholar +1 more source
Bispecific Antibodies: From Research to Clinical Application
Frontiers in Immunology, 2021 Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different antigens or two different epitopes on the same antigen. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with ...
Jiabing Ma +8 more
semanticscholar +1 more source
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]
PLoS ONE, 2018 Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li +8 more
doaj +1 more source
Bispecific antibodies in multiple myeloma treatment: A journey in progress
Frontiers in Oncology, 2022 The incorporation of novel agents and monoclonal antibody-based therapies into the treatment of multiple myeloma (MM) has significantly improved long-term patient survival.
Shih-Feng Cho +3 more
semanticscholar +1 more source
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Frontiers in Immunology, 2023 The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia +24 more
doaj +1 more source
T-cell redirecting bispecific antibodies in multiple myeloma: a revolution?
Blood, 2022 Bispecific antibodies are designed to link a surface target molecule on the malignant plasma cells to CD3 on T-cells and thereby redirect activated T-cells to induce tumor cell death.
P. Moreau, C. Touzeau
semanticscholar +1 more source
JAMA Network Open, 2022 Key Points Question Is there equitable geographic access to chimeric antigen receptor–T cells (CAR-T) and bispecific antibodies trials for multiple myeloma in the US?
Raghad Alqazaqi +8 more
semanticscholar +1 more source
American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023 Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski +4 more
wiley +1 more source